A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
for
Early Breast Cancer
Location: Fountain Valley CA
Sponsor: Genentech, Inc.
Sex: Female
Age: 18+
Code: NCT07541079
Phase3, Recruiting
Featured
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
for
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer,
Location: Boston MA, Philadelphia PA, Charlotte NC, Germantown TN,
Sponsor: Hoffmann-La Roche
Sex: Female
Age: 18+
Code: NCT04802759
Phase1, Phase2, Recruiting
Featured
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
for
Metastatic Breast Cancer
Location: Moncton, Boston MA, Quebec, Montreal, Hyattsville MD,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT05894239
Phase3, Recruiting
Featured
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
for
Breast Cancer
Location: East Brunswick NJ, Jacksonville FL, Los Angeles CA
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT07368998
Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Featured
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
for
Breast Cancer
Location: Grand Rapids MI, San Antonio TX
Sponsor: Genentech, Inc.
Sex: All
Age: 18+
Code: NCT07214662
Phase1, Recruiting
Featured
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
for
Breast Cancer
Location: East Patchogue NY, The Bronx NY, New Brunswick NJ,
Sponsor: Genentech, Inc.
Sex: All
Age: 18+
Code: NCT07100106
Phase1, Phase2, Recruiting
Featured
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer